Gene · 55
Papers3,704
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 3,704
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review. | Prostate Cancer | 2022 | 36474619 | PubTator, text mining | PubMed |
| Artificial genetic polymers against human pathologies. | Biol Direct | 2022 | 36474260 | PubTator, text mining | PubMed |
| Phospholipid-Membrane-Based Nanovesicles Acting as Vaccines for Tumor Immunotherapy: Classification, Mechanisms and Applications. | Pharmaceutics | 2022 | 36432636 | PubTator, text mining | PubMed |
| Current Developments in Cellular Therapy for Castration Resistant Prostate Cancer: A Systematic Review of Clinical Studies. | Cancers (Basel) | 2022 | 36428811 | PubTator, text mining | PubMed |
| SMARCC2 mediates the regulation of DKK1 by the transcription factor EGR1 through chromatin remodeling to reduce the proliferative capacity of glioblastoma. | Cell Death Dis | 2022 | 36418306 | PubTator, text mining | PubMed |
| Presumptive Prostate Cancer Presenting as Low Back Pain in the Chiropractic Office: Two Cases and Literature Review. | Cureus | 2022 | 36415398 | PubTator, text mining | PubMed |
| Metabolic Plasticity of Cancer Stem Cells in Response to Microenvironmental Cues. | Cancers (Basel) | 2022 | 36358763 | PubTator, text mining | PubMed |
| Perfluoroalkyl substances (PFASs) decrease the expression of recombination-activating genes (RAG1 and RAG2) in human B lymphoma Namalwa cells. | Arch Toxicol | 2022 | 36326898 | PubTator, text mining | PubMed |
| Intravenous administration of viral vectors expressing prostate cancer antigens enhances the magnitude and functionality of CD8+ T cell responses. | J Immunother Cancer | 2022 | 36323434 | PubTator, text mining | PubMed |
| Biomimetic Nanovesicles-Sources, Design, Production Methods, and Applications. | Pharmaceutics | 2022 | 36297442 | PubTator, text mining | PubMed |
| Preclinical and Clinical Research Models of Prostate Cancer: A Brief Overview. | Life (Basel) | 2022 | 36295041 | PubTator, text mining | PubMed |
| The Extracellular Molecular Chaperone Clusterin Inhibits Amyloid Fibril Formation and Suppresses Cytotoxicity Associated with Semen-Derived Enhancer of Virus Infection (SEVI). | Cells | 2022 | 36291126 | PubTator, text mining | PubMed |
| Progress in the Surface Functionalization of Selenium Nanoparticles and Their Potential Application in Cancer Therapy. | Antioxidants (Basel) | 2022 | 36290687 | PubTator, text mining | PubMed |
| Dynamics of antioxidant heme oxygenase-1 and pro-oxidant p66Shc in promoting advanced prostate cancer progression. | Free Radic Biol Med | 2022 | 36265795 | PubTator, text mining | PubMed |
| A literature perspective on the pharmacological applications of yohimbine. | Ann Med | 2022 | 36263866 | PubTator, text mining | PubMed |
| Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. | Front Endocrinol (Lausanne) | 2022 | 36263323 | PubTator, text mining | PubMed |
| Identification of pyroptosis-related lncRNA signature and AC005253.1 as a pyroptosis-related oncogene in prostate cancer. | Front Oncol | 2022 | 36248980 | PubTator, text mining | PubMed |
| miR-aculous new avenues for cancer immunotherapy. | Front Immunol | 2022 | 36248881 | PubTator, text mining | PubMed |
| The prevalence and prognosis of next-generation therapeutic targets in metastatic castration-resistant prostate cancer. | Mol Oncol | 2022 | 36209367 | PubTator, text mining | PubMed |
| Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer. | Front Immunol | 2022 | 36203594 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/55/papers?page=14